Skip to main content
Log in

27-Hydroxycholesterol inhibits trophoblast fusion during placenta development by activating PI3K/AKT/mTOR signaling pathway

  • Molecular Toxicology
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Trophoblast cell syncytialization is essential for placental and fetal development. Abnormal trophoblast cell fusion leads to pregnancy pathologies, such as preeclampsia (PE), intrauterine growth restriction (IUGR), and miscarriage. 27-hydroxycholesterol (27-OHC) is the most abundant oxysterol in human peripheral blood synthesized by sterol 27-hydroxylase (CYP27A1) and is considered a critical mediator between hypercholesterolemia and a variety of related disorders. Gestational hypercholesterolemia was associated with spontaneous preterm delivery and low birth weight (LBW) in term infants, yet the mechanism is unclear. In this study, two trophoblast cell models and CD-1 mice were used to evaluate the effects of 27-OHC on trophoblast fusion during placenta development. Two different kinds of trophoblast cells received a dosage of 2.5, 5, or 10 uM 27-OHC. Three groups of pregnant mice were randomly assigned: control, full treatment (E0.5-E17.5), or late treatment (E13.5-E17.5). All mice received daily intraperitoneal injections of saline (control group) and 27-OHC (treatment group; 5.5 mg/kg). In vitro experiments, we found that 27-OHC inhibited trophoblast cell fusion in primary human trophoblasts (PHT) and forskolin (FSK)-induced BeWo cells. 27-OHC up-regulated the expression of the PI3K/AKT/mTOR signaling pathway-related proteins. Moreover, the PI3K inhibitor LY294002 rescued the inhibitory effect of 27-OHC. Inhibition of trophoblast cell fusion by 27-OHC was also observed in CD-1 mice. Furthermore, fetal weight and placental efficiency decreased and fetal blood vessel development was inhibited in pregnant mice treated with 27-OHC. This study was the first to prove that 27-OHC inhibits trophoblast cell fusion by Activating PI3K/AKT/mTOR signaling pathway. This study reveals a novel mechanism by which dyslipidemia during pregnancy results in adverse pregnancy outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets generated during and analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

27-OHC:

27-Hydroxylcholesterol

CYP27A1:

Sterol 27-hydroxylase

LXR:

Liver X receptor

LBW:

Low birth weight

HDL-c:

Higher lipoprotein–cholesterol

SGA:

Small-for-gestational-age

oxHDL:

Oxidized higher lipoprotein

FSK:

Forskolin

GDM:

Gestational diabetes

IUGR:

Intrauterine growth restriction

STB:

Syncytiotrophoblast

CTB:

Cytotrophoblast

PE:

Preeclampsia

PHT:

Primary human trophoblasts

CCK-8:

Counting Kit-8

DAPI:

4′,6-Diamidino-2-phenylindole

HCG:

Human chorionic gonadotropin

GCM1:

Glial cell missing 1

PLAP:

Placental alkaline phosphatase

GFP:

Green fluorescence protein

p-PI3K:

Phospho-PI3 K

p-AKT:

Phospho-AKT

p-mTOR:

Phospho-mTOR

H&E:

Hematoxylin and Eosin

MHC:

Maternal hypercholesterolemia

PBS:

Phosphate-buffered saline

FBS:

Fetal bovine serum

DMSO:

Dimethyl sulfoxide

MOI:

Multiplicity of infection

References

Download references

Funding

This study was supported by the National Natural Science Foundation in China Grants (81872608).

Author information

Authors and Affiliations

Authors

Contributions

HY, RX, and XC designed the experiments. HZ, YZ, YZ collected the human samples. XZ, QD performed in experiments in vitro. QY and MZ performed in animal experiments. ZH and YW analyzed the data. XZ wrote the article. HY and XJ revised the manuscript. All authors contributed to the article and approved the submitted version.

Corresponding author

Correspondence to Huanling Yu.

Ethics declarations

Conflict of interest

The authors and the sponsor declare no competing interests.

Ethics statement

Our studies include human participants, human data, or human tissues. All the patients provided written informed consent before sampling and for the use of their clinical and biological data. This study was approved by the Ethics Committee of Capital Medical University and Fuxing Hospital affiliated to Capital Medical University (2018SY04). All clinical investigations were conducted according to the Declaration of Helsinki principles, and informed consent was obtained from all study participants. Animal experiments were conducted in accordance with the National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee at Capital Medical University (AEEI-2021-163).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 787 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, X., Cai, X., Zhu, H. et al. 27-Hydroxycholesterol inhibits trophoblast fusion during placenta development by activating PI3K/AKT/mTOR signaling pathway. Arch Toxicol 98, 849–863 (2024). https://doi.org/10.1007/s00204-023-03664-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-023-03664-4

Keywords

Navigation